Jeffrey Rathmell Archives
May. 5, 2022—The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.
Nov. 11, 2021—A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.
Apr. 7, 2021—Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.
Nov. 1, 2018—The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.
May. 10, 2018—W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
Nov. 10, 2016—At the intersection of immunology and metabolism is a burgeoning new field: immunometabolism. It’s an area where Vanderbilt has exceptional strengths, said Jeffrey Rathmell, Ph.D., Cornelius Vanderbilt Professor of Immunobiology.
May. 19, 2016—A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures.